Page 161 - Drug Class Review
P. 161
Drug Effectiveness Review Project
Drugs Author and Year: Reisberg et al., 2003; 59 Rive et al., 2004; 76 Doody et al., 2004 77 Merz Pharmaceuticals; NIH To assess the efficacy of MEM in outpatients with moderate to severe AD Setting: Multi-center (32) placebo memantine N/A 20 mg/d 28 weeks 28 weeks 126 126 Probable AD according to DSM-IV and NINCDS/ARDA criteria; baseline MMSE scores of 3 - 14; stage of 5 or 6 on the GDS; stage of 6a or greater on the Functional Assessment Staging Instrument; reliable caregivers; CT or MRI of the brain within previous 12 months VaD; clinically significant neurological
Alzheimer Country: US Study design: RCT Sample size: 252 conditions
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
